[go: up one dir, main page]

YU46640B - Postupak za dobijanje farmaceutskog preparata cefuroksim aksetila - Google Patents

Postupak za dobijanje farmaceutskog preparata cefuroksim aksetila

Info

Publication number
YU46640B
YU46640B YU92788A YU92788A YU46640B YU 46640 B YU46640 B YU 46640B YU 92788 A YU92788 A YU 92788A YU 92788 A YU92788 A YU 92788A YU 46640 B YU46640 B YU 46640B
Authority
YU
Yugoslavia
Prior art keywords
lipid
particles
cefuroxime axetil
mixture
preparation
Prior art date
Application number
YU92788A
Other languages
English (en)
Other versions
YU92788A (en
Inventor
M.B. James
L.G. Elliott
Original Assignee
Glaxo Group Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26292243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU46640(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB878711432A external-priority patent/GB8711432D0/en
Priority claimed from GB888802926A external-priority patent/GB8802926D0/en
Application filed by Glaxo Group Ltd. filed Critical Glaxo Group Ltd.
Priority to SI8810927A priority Critical patent/SI8810927B/sl
Publication of YU92788A publication Critical patent/YU92788A/xx
Publication of YU46640B publication Critical patent/YU46640B/sh
Priority to HR940557A priority patent/HRP940557B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

POSTUPAK ZA DOBIJANJE FARMACEUTSKOG PREPARATA CEFUROKSIM AKSETILA, koji obuhvata prvi stupanj dispergovanja delica cefuroksim aksetila, kao sto je amorfni cefuroksim aksetil, kao rasprsivanjem osuseni cefuroksim aksetil u obliku supljikavih mikrosfera, pri cemu pomenuti delici pozeljno imaju prosecan precnik delica po zapremini od 5 do 50 mikrometara, a po potrebi se prethodno prevlace sredstvom koje obrazuje u vodi rastvoran film, kao sto je polisaharid, alkilceluloza, hidroksialkil-celuloza, polivinilpirolidon alkilceluloza, hidroksialkilceluloza, polivinilpirolidon ili metakrilatni polimer, u istopljenom lipidu ili smesi lipida koji su nerastvorni u vodi ali su rastvorni ili se disperguju u gastrointestinalnom fluidu, pri cemu je pomenuti lipid ili smesa odabran medju zasicenim ili nezasicenim alifaticnim karbonskim kiselinama ravnog niza sa 10 do 30 atoma ugljenika, kao sto su smesa stearinske i palmitinske kiseline u masenom odnosu od 3:7 do 7:3, pozeljno oko 1:1, gliceril estri ovih kiselina, i alifaticni alkoholi sa 10 do 30 atoma ugljenika, pri cemu je tacka topljenja ovog lipida ili smese lipida u opsegu od 30-80 C, pozeljno 40-70 C, podesno u takvim kolicinama da disperzija sadrzi 5-50 mas.%, pozeljno 5-30 mas.% cefuroksim aksetila; drugi stupanj propustanja disperzije kroz atomizer, kao sto je atomizer sa pneumatskom prskalicom, podesno sa unutrasnjim mesanjem dva fluida; i treci stupanj hladjenja i sakupljanja tako dobijenih delica, naznacen time, sto se lipid ili smesa lipida upotrebljena u drugom stupnju odrzava na temperaturi od 10-20 C visoj od njihove tacke topljenja, pri cemu se dobijaju nerazgradjeni delici cefuroksim aksetila sa integralnim u vodi nerastvornim prevlakama lipida ili smese lipida, pri cemu ovi delici imaju precnik u opsegu od 1 do 250 mikrometara. Prijava sadrzi jos 1 nezavisan i 1 zavisan patentni zahtev.
YU92788A 1987-05-14 1988-05-13 Postupak za dobijanje farmaceutskog preparata cefuroksim aksetila YU46640B (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI8810927A SI8810927B (sl) 1987-05-14 1988-05-13 Postopek za pripravo farmacevtskega pripravka cefuroksim aksetila
HR940557A HRP940557B1 (en) 1987-05-14 1994-09-16 Process for the preparation of ceruroxime axetil as pharmaceutical preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878711432A GB8711432D0 (en) 1987-05-14 1987-05-14 Pharmaceutical composition
GB888802926A GB8802926D0 (en) 1988-02-09 1988-02-09 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
YU92788A YU92788A (en) 1990-06-30
YU46640B true YU46640B (sh) 1994-01-20

Family

ID=26292243

Family Applications (1)

Application Number Title Priority Date Filing Date
YU92788A YU46640B (sh) 1987-05-14 1988-05-13 Postupak za dobijanje farmaceutskog preparata cefuroksim aksetila

Country Status (38)

Country Link
US (1) US4865851A (sh)
JP (1) JPH0778023B2 (sh)
KR (1) KR950009097B1 (sh)
CN (1) CN1054508C (sh)
AT (1) AT393794B (sh)
AU (1) AU607996B2 (sh)
BE (1) BE1000956A5 (sh)
CA (1) CA1328405C (sh)
CH (1) CH675357A5 (sh)
CY (1) CY1600A (sh)
CZ (1) CZ280884B6 (sh)
DE (1) DE3816464C3 (sh)
DK (1) DK175593B1 (sh)
ES (1) ES2009915A6 (sh)
FI (1) FI90825C (sh)
FR (1) FR2615101B1 (sh)
GB (1) GB2204792B (sh)
GR (1) GR1000357B (sh)
HK (1) HK106191A (sh)
HU (1) HU200927B (sh)
IE (1) IE61693B1 (sh)
IL (1) IL86359A (sh)
IT (1) IT1219941B (sh)
MY (1) MY103525A (sh)
NL (1) NL193682C (sh)
NO (1) NO176695C (sh)
NZ (1) NZ224598A (sh)
PH (1) PH26015A (sh)
PL (1) PL272429A1 (sh)
PT (1) PT87474B (sh)
RU (1) RU1837876C (sh)
SA (1) SA91120129B1 (sh)
SE (2) SE466047B (sh)
SG (1) SG51491G (sh)
SK (1) SK277898B6 (sh)
UA (1) UA12335A (sh)
YU (1) YU46640B (sh)
ZW (1) ZW5988A1 (sh)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
US5356644A (en) * 1989-01-25 1994-10-18 Pfizer Inc. Low calorie fat substitute
FR2649608B1 (fr) * 1989-07-12 1991-10-11 Oreal Composition cosmetique sous forme d'un gel aqueux contenant en suspension des spheroides d'une substance lipidique solide non hydrophile
US5674504A (en) * 1989-07-12 1997-10-07 L'oreal Cosmetic composition in the form of an aqueous gel containing in suspension spheroids of a non-hydrophilic, lipoidal substance
FR2660554B1 (fr) * 1990-04-05 1992-07-03 Oreal Composition cosmetique ou dermo-pharmaceutique aqueuse contenant en suspension des spherouides hydrates d'une substance lipidique hydrophile.
DE69129036T2 (de) * 1990-11-30 1998-07-30 Yamanouchi Pharma Co Ltd Überdeckte zusammensetzung mit schneller freisetzung
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
US5320848A (en) * 1991-05-28 1994-06-14 Affinity Biotech, Inc. Chewable drug-delivery composition
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
WO1994005260A1 (en) * 1992-09-03 1994-03-17 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
WO1994008576A1 (en) * 1992-10-16 1994-04-28 Glaxo Group Limited Taste-masking compositions of ranitidine
KR0168715B1 (ko) * 1992-11-30 1999-01-15 밋첼 아이. 커시너 맛을 차단하는 약제학적 조성물
IT1264020B (it) * 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
WO1994025006A1 (en) * 1993-04-26 1994-11-10 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
US7060293B1 (en) * 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US5728403A (en) * 1994-10-05 1998-03-17 The Board Of Regents Of The University Of Nebraska Coating technology for taste masking orally administered bitter drugs
BE1009257A3 (nl) * 1995-03-21 1997-01-07 Universiteit Gent Lab Voor Far Farmaceutische matrix.
GB9702799D0 (en) * 1997-02-12 1997-04-02 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
US6242019B1 (en) * 1997-08-14 2001-06-05 Warner-Lambert Company Taste modified hard confectionery compositions containing functional ingredients
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
IN186539B (sh) * 1997-09-29 2001-09-29 Ranbaxy Lab Ltd
ES2362418T3 (es) * 1997-12-08 2011-07-05 Nycomed Gmbh Nueva forma de supositorio que comprende un compuesto activo ácido-lábil.
US5891476A (en) * 1997-12-22 1999-04-06 Reo; Joe P. Tastemasked pharmaceutical system
US20020009478A1 (en) * 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
AT413647B (de) * 1998-11-26 2006-04-15 Sandoz Ag Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
CN1343128B (zh) * 1999-03-17 2010-04-21 第一制药株式会社 药物组合物
IN190831B (sh) * 1999-03-19 2003-08-23 Ranbaxy Lab Ltd
EP1165042B1 (fr) 1999-04-06 2005-02-02 Ethypharm Suspension pharmaceutique buvable d'ibuprofene
IN191239B (sh) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
JP2002138034A (ja) * 2000-10-27 2002-05-14 Kyoto Pharmaceutical Industries Ltd 苦味マスキングチュアブル錠およびその製造方法
EP1414417A4 (en) * 2000-12-01 2004-05-06 Abdul Rehman Khan PHARMACEUTICAL FORMULATION
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
US6589955B2 (en) 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
WO2003020241A2 (en) * 2001-09-05 2003-03-13 Vectura Limited Functional powders for oral delivery
HRP20020924A2 (en) * 2001-11-23 2003-10-31 Glaxo Group Ltd Pharmaceutical composition
KR20030055571A (ko) * 2001-12-27 2003-07-04 주식회사 백텍 카르복실 메틸 세룰로오스를 이용한 서방성마이크로스피어 제제의 개발
US20030170310A1 (en) * 2002-03-08 2003-09-11 Hardeep Wadhwa Tasteless, directly compressible, fast-dissolving complexes and pharmaceutical formulations thereof
EP1482789A4 (en) * 2002-03-12 2010-12-29 Toyama Chemical Company Ltd TASTY ORAL SUSPENSION AND METHOD
KR100523082B1 (ko) * 2002-09-11 2005-10-20 (주)다산메디켐 쓴 맛이 은폐된 세푸록심악세틸 제제의 제약조성물 및 그의 제조방법
US20060018972A1 (en) * 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
US20100092562A1 (en) * 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
US20040146553A1 (en) * 2002-12-23 2004-07-29 Aventis Pharma S.A. Compositions for oral administration of active principles requiring masking of taste
FR2848855B1 (fr) * 2002-12-23 2005-02-11 Aventis Pharma Sa Compositions pour administration orale de principes actifs necessitant un masquage du gout
WO2005002540A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Dry powder pharmaceutical suspension compositions of cefuroxime axetil
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
KR100801589B1 (ko) 2004-01-09 2008-02-05 한미약품 주식회사 세푸록심 악세틸 과립 및 이의 제조방법
WO2005065658A1 (en) * 2004-01-09 2005-07-21 Hanmi Pharm. Co., Ltd. Cefuroxime axetil granule and process for the preparation thereof
TR200606412T2 (tr) * 2004-03-19 2007-01-22 Eczaciba�I �Zg�N K�Myasal �R�Nler San. Ve T�C. A �. Lipit kaplı sefuroksim aksetil hazırlanması
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US7727576B2 (en) * 2004-04-16 2010-06-01 Hewlett-Packard Development Company, L.P. System and a method for producing layered oral dosage forms
GB2419094A (en) 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
WO2006061846A1 (en) * 2004-12-10 2006-06-15 Council Of Scientific And Industrial Research Pharmaceutical composition for improving palatability of drugs and process for preparation thereof
US7378109B2 (en) * 2004-12-23 2008-05-27 Council Of Scientific And Industrial Research Pharmaceutical composition for improving palatability of drugs and process for preparation thereof
DE102005019458A1 (de) * 2005-04-25 2006-10-26 Grünenthal GmbH Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil
US20060292225A1 (en) * 2005-06-24 2006-12-28 Felix Arthur M Water soluble analgesic formulations and methods for production
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
JP5925296B2 (ja) * 2011-04-20 2016-05-25 ディーエスエム アイピー アセッツ ビー．ブイ． カロテノイドを含む小ビーズ
EP2741750A1 (en) 2011-08-12 2014-06-18 Dhanuka Laboratories Ltd. Pharmaceutical composition comprising cefuroxime
CN102440960A (zh) * 2011-09-01 2012-05-09 山东鲁抗医药股份有限公司 一种头孢呋辛酯干混悬剂药物组合物及其制备方法
WO2013038323A1 (en) 2011-09-13 2013-03-21 Unimark Remedies Ltd. Taste masked pharmaceutical compositions of cefuroxime axetil
MX351421B (es) * 2011-10-14 2017-10-13 Dsm Ip Assets Bv Nuevo sistema de recubrimiento.
HUE060093T2 (hu) 2012-03-15 2023-01-28 Boehringer Ingelheim Vetmedica Gmbh Gyógyszerészeti tablettakészítmény az állatgyógyászati ágazat számára, eljárás annak elõállítására és annak alkalmazása
CN103330683B (zh) * 2013-06-26 2014-12-03 神威药业集团有限公司 一种富马酸替诺福韦酯细粒剂
WO2015007760A1 (en) 2013-07-19 2015-01-22 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CN103610680B (zh) * 2013-11-07 2015-12-30 国药集团致君（深圳）制药有限公司 一种头孢呋辛酯组合物及其制备方法
CA3176466A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
KR101899773B1 (ko) * 2017-03-07 2018-09-18 일동제약(주) 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법
CN107233317B (zh) * 2017-05-25 2020-07-24 北京万鹏朗格医药科技有限公司 一种含精氨酸布洛芬的药物组合物及其制备方法
KR102044676B1 (ko) * 2019-03-27 2019-11-14 주식회사 씨트리 생체적합성 고분자 기반 아픽사반 함유 미립구의 제조방법
CN112516076B (zh) * 2020-12-16 2024-05-03 郑州百瑞动物药业有限公司 一种头孢噻呋注射用原位凝胶及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
GB922697A (en) * 1958-12-01 1963-04-03 Merck & Co Inc Coated vitamin preparations and a process for making them
US3080293A (en) * 1960-08-02 1963-03-05 Hoffmann La Roche Process of making pleasant-tasting niacinamide beadlets
GB1323161A (en) * 1970-02-16 1973-07-11 Wyeth John & Brother Ltd Penicillin composition
DE2115116C3 (de) * 1970-03-27 1982-04-15 Sankyo Co., Ltd., Tokyo Gleitmittel und Verfahren zu dessen Herstellung
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
JPS51112564A (en) * 1975-03-28 1976-10-05 Ajinomoto Kk Production of nutritive matearial for diet food
DE2950977A1 (de) * 1978-12-22 1980-07-10 Donald E Panoz Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung
JPS6029682B2 (ja) * 1980-07-11 1985-07-12 山之内製薬株式会社 苦味のない製剤用組成物およびその製造法
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
YU44680B (en) 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
US4533542A (en) * 1983-08-22 1985-08-06 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
US4764375A (en) * 1985-09-11 1988-08-16 Kv Pharmaceutical Company Sachet drug delivery system
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
KR880013560A (ko) 1988-12-21
SK277898B6 (en) 1995-07-11
BE1000956A5 (fr) 1989-05-23
JPH0778023B2 (ja) 1995-08-23
CH675357A5 (sh) 1990-09-28
YU92788A (en) 1990-06-30
NZ224598A (en) 1989-08-29
FI882253A0 (fi) 1988-05-13
DE3816464C3 (de) 2001-12-20
HUT47022A (en) 1989-01-30
IT8847962A0 (it) 1988-05-13
NL193682B (nl) 2000-03-01
NL193682C (nl) 2000-07-04
GB2204792A (en) 1988-11-23
GB8811378D0 (en) 1988-06-15
ES2009915A6 (es) 1989-10-16
IL86359A0 (en) 1988-11-15
MY103525A (en) 1993-07-31
AU1615788A (en) 1988-11-17
CS403391A3 (en) 1992-08-12
US4865851A (en) 1989-09-12
NO882123L (no) 1988-11-15
KR950009097B1 (ko) 1995-08-14
FI882253A (fi) 1988-11-15
DE3816464C2 (de) 1996-08-29
DE3816464A1 (de) 1988-11-24
DK263288D0 (da) 1988-05-13
NO176695C (no) 1995-05-16
GR1000357B (el) 1992-06-25
IE61693B1 (en) 1994-11-16
NO176695B (no) 1995-02-06
NO882123D0 (no) 1988-05-13
FR2615101A1 (fr) 1988-11-18
FR2615101B1 (fr) 1992-02-07
UA12335A (uk) 1996-12-25
DK263288A (da) 1988-11-15
GR880100317A (en) 1989-02-23
PT87474B (pt) 1992-09-30
AT393794B (de) 1991-12-10
DK175593B1 (da) 2004-12-13
PT87474A (pt) 1989-05-31
ZW5988A1 (en) 1990-04-04
HK106191A (en) 1992-01-03
SA91120129B1 (ar) 2004-08-29
PL272429A1 (en) 1989-02-20
CA1328405C (en) 1994-04-12
CZ280884B6 (cs) 1996-04-17
HU200927B (en) 1990-09-28
NL8801236A (nl) 1988-12-01
JPS63303928A (ja) 1988-12-12
SE8801813D0 (sv) 1988-05-13
FI90825C (fi) 1994-04-11
ATA125988A (de) 1991-06-15
IE881452L (en) 1988-11-14
CN1054508C (zh) 2000-07-19
AU607996B2 (en) 1991-03-21
SE466047B (sv) 1991-12-09
IL86359A (en) 1992-11-15
PH26015A (en) 1992-01-29
RU1837876C (ru) 1993-08-30
GB2204792B (en) 1991-01-23
SE8801813L (sv) 1988-11-15
CN88102851A (zh) 1988-12-21
SG51491G (en) 1991-08-23
CY1600A (en) 1992-04-03
IT1219941B (it) 1990-05-24
FI90825B (fi) 1993-12-31

Similar Documents

Publication Publication Date Title
YU46640B (sh) Postupak za dobijanje farmaceutskog preparata cefuroksim aksetila
DE69101493T2 (de) Verfahren zur Herstellung kugelförmiger Arzneimittel.
DE3049179C2 (sh)
EP0896603B1 (de) In wässriger lösung redispergierbare polymerpulver
DE69118592T3 (de) Verfahren zur Herstellung von Wirkstoffgranulaten durch Extrudierung
AU693539B2 (en) Apparatus and method for preparing solid forms with controlled release of the active ingredient
US5389380A (en) Sustained release pharmaceutical preparation and process for preparing the same
EP0299344B1 (de) Staubarmes sprühgetrocknetes Emulsionspolymerisat und Verfahren zu seiner Herstellung und Anwendung
JPH0534335B2 (sh)
JPH012554A (ja) 被覆アミノ酸類の製造方法
ES525794A0 (es) Procedimiento para la preparacion de un granulado de polimero
EP0332067A1 (de) Verfahren zur Herstellung sprühgetrockneter Emulsionspolymerisate
OA10257A (en) Process for coating droplets or nanometric particles
ATE234116T1 (de) Agglomerate oder sphärische teilchen aus polyvalenten metall-alginaten, an die agglomerate gebundene zusammensetzungen für die kontrollierte freisetzung, die schwerlösliche medikamente enthalten, und verfahren für ihre herstellung
JPS5973529A (ja) 被覆固形製剤の製造法
JPH0759502B2 (ja) 調節放出型剤形用の乾式直接圧縮組成物
ATE258794T1 (de) Ein chinolonderivat enthaltendes arzneimittel und verfahren zu dessen herstellung
DE69327279T2 (de) Verfahren zur Herstellung von Zusammensetzungen für Wiederkäuer
Öner et al. Optimization of conditions for preparing 2-to 5-micron-range gelatin microparticles by using chilled dehydration agents
JPS63164864A (ja) 水溶性ビタミン類被覆製剤の製造方法
JP5042447B2 (ja) 混合製剤
SI8810927B (sl) Postopek za pripravo farmacevtskega pripravka cefuroksim aksetila
CN115152900A (zh) 一种过瘤胃包衣制剂及其制备方法和应用
JPS5951223A (ja) 製剤組成物
JPS597685B2 (ja) ビタミン製剤の製造法